Información de Johnson & Johnson, dividendo de Johnson & Johnson, actividades de los accionistas y más

Más Datos de Johnson & Johnson Compañía

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

Información de Johnson & Johnson



Símbolo de cotizaciónJNJ

Nombre de la empresaJohnson & Johnson

Fecha de salida a bolsaOct 31, 2080

Director ejecutivoDuato (Joaquin Boix)

Número de empleados138100

Tipo de seguridadOrdinary Share

Fin del año fiscalOct 31

DirecciónOne Johnson & Johnson Plaza

CiudadNEW BRUNSWICK

Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE

PaísUnited States of America

Código postal08933

Teléfono17325242455

Sitio Webhttps://www.jnj.com/

Símbolo de cotizaciónJNJ

Fecha de salida a bolsaOct 31, 2080

Director ejecutivoDuato (Joaquin Boix)

Ejecutivos de Johnson & Johnson



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Joaquin Boix Duato

Chairman of the Board, Chief Executive Officer

276.91K

--

Ms. Jennifer L. Taubert

Executive Vice President, Worldwide Chairman, Innovative Medicine

178.01K

--

Ms. Kathryn E. Wengel

Executive Vice President, Chief Technology Officer and Risk Officer

94.62K

+12015.00%

Mr. Joseph J. Wolk

Chief Financial Officer, Executive Vice President

84.95K

--

Ms. Vanessa Broadhurst

Executive Vice President - Global Corporate Affairs

23.59K

+3760.00%

Ms. Kristen Mulholland

Chief Human Resources Officer, Executive Vice President

14.12K

+2430.00%

Ms. Elizabeth (Liz) Forminard

Executive Vice President, Chief Legal Officer

12.85K

+1951.00%

Prof. Dr. John C. Reed, M.D., Ph.D.

Executive Vice President - Innovative Medicine, Research and Development

10.66K

--

Mr. Hubert Joly

Independent Director

5.00K

--

Ms. Marillyn A. Hewson

Lead Independent Director

3.00K

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Joaquin Boix Duato

Chairman of the Board, Chief Executive Officer

276.91K

--

Ms. Jennifer L. Taubert

Executive Vice President, Worldwide Chairman, Innovative Medicine

178.01K

--

Ms. Kathryn E. Wengel

Executive Vice President, Chief Technology Officer and Risk Officer

94.62K

+12015.00%

Mr. Joseph J. Wolk

Chief Financial Officer, Executive Vice President

84.95K

--

Ms. Vanessa Broadhurst

Executive Vice President - Global Corporate Affairs

23.59K

+3760.00%

Ms. Kristen Mulholland

Chief Human Resources Officer, Executive Vice President

14.12K

+2430.00%

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Oncology-DARZALEX

3.67B

15.30%

Immunology-STELARA

1.57B

6.54%

Immunology-TREMFYA

1.42B

5.94%

Cardiovascular-ELECTROPHYSIOLOGY

1.42B

5.91%

Surgery-General

1.38B

5.74%

Otro

14.53B

60.56%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

13.71B

57.13%

Europe

5.44B

22.67%

Asia-Pacific, Africa

3.61B

15.06%

Western Hemisphere, excluding U.S.

1.23B

5.13%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Oncology-DARZALEX

3.67B

15.30%

Immunology-STELARA

1.57B

6.54%

Immunology-TREMFYA

1.42B

5.94%

Cardiovascular-ELECTROPHYSIOLOGY

1.42B

5.91%

Surgery-General

1.38B

5.74%

Otro

14.53B

60.56%

Estadísticas de accionistas

Actualizado: lun., 17 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

10.10%

State Street Investment Management (US)

5.49%

BlackRock Institutional Trust Company, N.A.

5.37%

Geode Capital Management, L.L.C.

2.33%

JP Morgan Asset Management

1.52%

Otro

75.18%

Accionistas

Proporción

The Vanguard Group, Inc.

10.10%

State Street Investment Management (US)

5.49%

BlackRock Institutional Trust Company, N.A.

5.37%

Geode Capital Management, L.L.C.

2.33%

JP Morgan Asset Management

1.52%

Otro

75.18%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

39.87%

Investment Advisor/Hedge Fund

24.21%

Research Firm

3.16%

Pension Fund

2.23%

Bank and Trust

2.07%

Insurance Company

1.61%

Sovereign Wealth Fund

1.41%

Hedge Fund

0.71%

Family Office

0.09%

Otro

24.63%

Participación institucional



Actualizado: jue., 1 de ene

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

6009

1.82B

75.35%

+8.67M

2025Q3

5885

1.79B

74.44%

+16.50K

2025Q2

5920

1.78B

73.89%

-7.65M

2025Q1

6002

1.80B

74.62%

+4.60M

2024Q4

5953

1.78B

74.14%

+8.28M

2024Q3

5699

1.77B

73.47%

+2.69M

2024Q2

5691

1.75B

72.75%

+9.12M

2024Q1

5685

1.73B

71.58%

-6.08M

2023Q4

5686

1.72B

71.40%

-7.80M

2023Q3

5524

1.72B

71.21%

-159.24M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

235.57M

9.78%

-454.61K

-0.19%

Sep 30, 2025

State Street Investment Management (US)

132.21M

5.49%

-591.27K

-0.45%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

129.42M

5.37%

-343.10K

-0.26%

Sep 30, 2025

Geode Capital Management, L.L.C.

56.22M

2.33%

-4.39M

-7.25%

Sep 30, 2025

JP Morgan Asset Management

36.60M

1.52%

-110.36K

-0.30%

Sep 30, 2025

State Farm Insurance Companies

34.11M

1.42%

-262.64K

-0.76%

Sep 30, 2025

Norges Bank Investment Management (NBIM)

31.93M

1.33%

+1.57M

+5.18%

Jun 30, 2025

Wellington Management Company, LLP

25.83M

1.07%

+956.24K

+3.84%

Sep 30, 2025

Morgan Stanley Smith Barney LLC

25.26M

1.05%

-42.23K

-0.17%

Sep 30, 2025

BlackRock Asset Management Ireland Limited

20.93M

0.87%

+1.08M

+5.46%

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

iShares U.S. Pharmaceuticals ETF

23.7%

VanEck Pharmaceutical ETF

10.06%

FT Vest DJIA Dogs 10 Target Income ETF

9.82%

Health Care Select Sector SPDR Fund

9.32%

Proshares Ultra Health Care

9%

iShares U.S. Healthcare ETF

8.9%

JPMorgan Healthcare Leaders ETF

8.38%

First Trust NASDAQ Pharmaceuticals ETF

8.28%

Fidelity MSCI Health Care Index ETF

7.67%

Franklin Income Focus ETF

7.08%

iShares U.S. Pharmaceuticals ETF

Proporción23.7%

VanEck Pharmaceutical ETF

Proporción10.06%

FT Vest DJIA Dogs 10 Target Income ETF

Proporción9.82%

Health Care Select Sector SPDR Fund

Proporción9.32%

Proshares Ultra Health Care

Proporción9%

iShares U.S. Healthcare ETF

Proporción8.9%

JPMorgan Healthcare Leaders ETF

Proporción8.38%

First Trust NASDAQ Pharmaceuticals ETF

Proporción8.28%

Fidelity MSCI Health Care Index ETF

Proporción7.67%

Franklin Income Focus ETF

Proporción7.08%

Dividendos



Un total de 46.31B USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Jan 02, 2026

JNJ.NB Final Cash Dividend of gross USD 1.3 paid on Mar 10, 2026 going ex on Feb 24, 2026

Feb 24, 2026

Mar 10, 2026

Feb 24, 2026

Jan 02, 2025

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025

Feb 18, 2025

Mar 04, 2025

Feb 18, 2025

Oct 15, 2024

JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024

Nov 26, 2024

Dec 10, 2024

Nov 26, 2024

Jul 17, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024

Aug 27, 2024

Sep 10, 2024

Aug 27, 2024

Apr 16, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024

May 21, 2024

Jun 04, 2024

May 20, 2024

Jan 02, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024

Feb 20, 2024

Mar 05, 2024

Feb 16, 2024

Oct 19, 2023

JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023

Nov 21, 2023

Dec 05, 2023

Nov 20, 2023

Jul 20, 2023

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023

Aug 28, 2023

Sep 07, 2023

Aug 25, 2023

Apr 18, 2023

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023

May 23, 2023

Jun 06, 2023

May 22, 2023

Jan 03, 2023

JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023

Feb 21, 2023

Mar 07, 2023

Feb 17, 2023

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos